PMID- 18519838
OWN - NLM
STAT- MEDLINE
DCOM- 20080904
LR  - 20221207
IS  - 1945-1997 (Electronic)
IS  - 0098-6151 (Linking)
VI  - 108
IP  - 5 Suppl 3
DP  - 2008 May
TI  - Reducing global cardiovascular risk in patients with type 2 diabetes mellitus.
PG  - S14-9
AB  - Type 2 diabetes mellitus (T2DM) and its complications must be managed by using a 
      comprehensive, or global, approach to treatment. The author describes the case of 
      a white man, aged 51 years, with T2DM that was diagnosed 3 years earlier. The 
      patient was obese and had a history of chronic low back pain. He also had 
      diagnosed hypertension, decreased vibratory sensation in the feet, an S4 atrial 
      gallop, trace ankle edema, degenerative joint disease in the knees, and decreased 
      range of motion in the lumbar spine. Other findings at the patient's initial 
      visit included hyperglycemia, microalbuminuria, and lipid abnormalities. Initial 
      treatment included metformin; a nonsteroidal anti-inflammatory drug (naproxen); a 
      thiazolidinedione (rosiglitazone maleate); a thiazide diuretic 
      (hydrochlorothiazide); an angiotensin-converting enzyme inhibitor (enalapril); 
      and low-dose aspirin. At 6-month follow-up, the patient continued to have 
      elevated glycosylated hemoglobin, hypertension, dyslipidemia, and excess weight. 
      Additional treatment strategies consisted of pioglitazone hydrochloride; 
      metformin in combination with the dipeptidyl peptidase IV inhibitor sitagliptin 
      phosphate; a statin (atorvastatin hydrochloride); and enrollment in a diet and 
      exercise program. Results at 12-month follow-up included a substantial decrease 
      in glycosylated hemoglobin and improved hypertension and dyslipidemia. The 
      patient was successfully treated across the full range of global cardiovascular 
      risk reduction.
FAU - Gavin, James R 3rd
AU  - Gavin JR 3rd
AD  - Healing Our Village, Inc., Lanham, Md., USA. jrgavin3@yahoo.com
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Am Osteopath Assoc
JT  - The Journal of the American Osteopathic Association
JID - 7503065
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Cardiovascular Diseases/etiology/*prevention & control
MH  - Diabetes Mellitus, Type 2/*complications/drug therapy
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Obesity/complications/prevention & control
EDAT- 2008/06/28 09:00
MHDA- 2008/09/05 09:00
CRDT- 2008/06/28 09:00
PHST- 2008/06/28 09:00 [pubmed]
PHST- 2008/09/05 09:00 [medline]
PHST- 2008/06/28 09:00 [entrez]
AID - 108/5_suppl_3/S14 [pii]
PST - ppublish
SO  - J Am Osteopath Assoc. 2008 May;108(5 Suppl 3):S14-9.